Scientists track Long-Term safety of approved growth hormone

NCT ID NCT05775523

Recruiting now Knowledge-focused Sponsor: Ascendis Pharma Endocrinology Division A/S Source: ClinicalTrials.gov ↗

Summary

This study aims to monitor the long-term safety of an already approved growth hormone treatment called lonapegsomatropin. It will follow 500 children with growth hormone deficiency in the US and Europe who are already receiving this treatment in real-world settings. The main goal is to watch for potential long-term side effects, such as tumors or diabetes, and compare the rates to what is already known from medical literature.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ascendis Investigational Site
RECRUITING

Phoenix, Arizona, 85054, United States
Ascendis Investigational Site
RECRUITING

Orange, California, 92868, United States
Ascendis Investigational Site
RECRUITING

Sacramento, California, 95821, United States
Ascendis Investigational Site
RECRUITING

San Francisco, California, 94143, United States
Ascendis Investigational Site
RECRUITING

Washington D.C., District of Columbia, 20010, United States
Ascendis Investigational Site
RECRUITING

Orlando, Florida, 32806, United States
Ascendis Investigational Site
RECRUITING

Orlando, Florida, 32827, United States
Ascendis Investigational Site
RECRUITING

Tampa, Florida, 33612, United States
Ascendis Investigational Site
RECRUITING

Sandy Springs, Georgia, 30350, United States
Ascendis Investigational Site
RECRUITING

Boise, Idaho, 83712, United States
Ascendis Investigational Site
RECRUITING

Indianapolis, Indiana, 46202, United States
Ascendis Investigational Site
RECRUITING

Iowa City, Iowa, 52242, United States
Ascendis Investigational Site
RECRUITING

Louisville, Kentucky, 40202, United States
Ascendis Investigational Site
RECRUITING

Minneapolis, Minnesota, 55455, United States
Ascendis Investigational Site
RECRUITING

Las Vegas, Nevada, 89113, United States
Ascendis Investigational Site
RECRUITING

Lebanon, New Hampshire, 03756, United States
Ascendis Investigational Site
RECRUITING

Manchester, New Hampshire, 03104, United States
Ascendis Investigational Site
RECRUITING

Morristown, New Jersey, 07960, United States
Ascendis Investigational Site
RECRUITING

New Hyde Park, New York, 11042, United States
Ascendis Investigational Site
RECRUITING

Cincinnati, Ohio, 45229, United States
Ascendis Investigational Site
RECRUITING

Portland, Oregon, 97239, United States
Ascendis Investigational Site
RECRUITING

Columbia, South Carolina, 29203, United States
Ascendis Investigational Site
RECRUITING

Dallas, Texas, 75390, United States
Ascendis Investigational Site
RECRUITING

El Paso, Texas, 79907, United States
Ascendis Investigational Site
RECRUITING

Norfolk, Virginia, 23507, United States
Ascendis Investigational Site
RECRUITING

Seattle, Washington, 98105, United States
Ascendis Pharma Investigational Site
RECRUITING

Centennial, Colorado, 80112, United States

Conditions

Explore the condition pages connected to this study.

GROWTH HORMONE DEFICIENCY